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Abstract
Objectives To investigate whether the use and timing of prescription of
β blockers in patients with chronic obstructive pulmonary disease (COPD)
having a first myocardial infarction was associated with survival and to
identify factors related to their use.
Design Population based cohort study in England.
Setting UK national registry of myocardial infarction (Myocardial
Ischaemia National Audit Project (MINAP)) linked to the General Practice
Research Database (GPRD), 2003-11.
Participants Patients with COPD with a first myocardial infarction in 1
January 2003 to 31 December 2008 as recorded in MINAP, who had
no previous evidence of myocardial infarction in their GPRD or MINAP
record. Data were provided by the Cardiovascular Disease Research
using Linked Bespoke studies and Electronic Health Records (CALIBER)
group at University College London.
Main outcome measure Cox proportional hazards ratio for mortality
after myocardial infarction in patients with COPD in those prescribed β
blockers or not, corrected for covariates including age, sex, smoking
status, drugs, comorbidities, type of myocardial infarction, and severity
of infarct.
Results Among 1063 patients with COPD, treatment with β blockers
started during the hospital admission for myocardial infarction was
associated with substantial survival benefits (fully adjusted hazard ratio
0.50, 95% confidence interval 0.36 to 0.69; P<0.001; median follow-up
time 2.9 years). Patients already taking a β blocker before their
myocardial infarction also had a survival benefit (0.59, 0.44 to 0.79;
P<0.001). Similar results were obtained with propensity scores as an
alternative method to adjust for differences between those prescribed
and not prescribed β blockers. With follow-up started from date of
discharge from hospital, the effect size was slightly attenuated but there
was a similar protective effect of treatment with β blockers started during
hospital admission for myocardial infarction (0.64, 0.44 to 0.94; P=0.02).
Conclusions The use of β blockers started either at the time of hospital
admission for myocardial infarction or before a myocardial infarction is
associated with improved survival after myocardial infarction in patients
with COPD.
Registration NCT01335672.
Introduction
Patients with chronic obstructive pulmonary disease (COPD)
are at increased risk of cardiovascular comorbidities, including
myocardial infarction1 and have decreased short and long term
survival after a myocardial infarction compared with patients
without COPD.2-6 COPD is currently the fourth leading cause
of death in the United States and Europe7 and is predicted to
become the third by 2020. Up to a third of deaths in patients
with COPD are attributable to cardiovascular disease8-11 and for
every 10% decrease in forced expiratory volume in one second
(FEV1), cardiovascular mortality increases by 28%.
8 While it is
likely that COPD itself contributes to an underlying increase in
mortality after myocardial infarction, there could be some
potentially modifiable risk factors.
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β blockers are effective at reducing risk of mortality and
re-infarction after myocardial infarction,12 13 and they might
reduce mortality in patients with COPD with acute coronary
syndromes.14 15 Despite increasing evidence that β blockers are
safe16 17 and can actually be beneficial in patients with COPD,
even beyond cardiovascular properties,18 their use continues to
be limited in this group. This is a worldwide phenomenon19 and
might be related to historical concerns that β blockers could be
harmful in patients with COPD (for example, by inducing
bronchospasm). Such concerns, however, have been challenged
by recent evidence.20 Cardioselective β blockers are less likely
to cause bronchospasm, and, additionally, the risk of
bronchospasm can be reduced by starting β blockers at a lower
dose and slowly titrating up.
Using linkedMyocardial Ischaemia National Audit Project data
(MINAP) and General Practice Research Database (GPRD)
data, we aimed to quantify the association between COPD and
mortality after myocardial infarction to investigate whether the
use and timing of prescription of β blockers in patients with
COPD after a first myocardial infarction was associated with
improved survival, and to identify factors related to the use of
β blockers in with COPD.
Methods
Dataset
For this analysis we used a CALIBER (Cardiovascular disease
research using linked bespoke studies and electronic health
records) dataset (http://caliberresearch.org.uk/), composed by
linkage of data from MINAP and GPRD. MINAP is a national
register recording hospital admissions for myocardial infarction
and other acute coronary syndromes, with participation from
all hospitals in England andWales that admit patients with these
conditions.21 GPRD is a large database of research standard
anonymised computerised primary care medical records from
about five million active patients from around 625 primary care
practices throughout the United Kingdom (www.gprd.com).22
About half of the practices have consented to linkage, and these
practices are based in England.
Study population
We included patients with COPD experiencing their first
myocardial infarction from 1 January 2003 to 31 December
2008 as recorded in MINAP, who had no previous evidence of
myocardial infarction in their GPRD or MINAP record. The
diagnosis of myocardial infarction was based on the international
definition by using discharge diagnosis, results of
electrocardiography results, andmarkers of myocardial necrosis.
Outcomes were assessed between the latest of 1 January 2003,
one year after registration with the practice, or one year after
the practice quality standards were met for inclusion in GPRD
and the earliest of the date of transfer out of the patient, death
of the patient, or 31 December 2008.We excluded patients aged
under 18, not registered with a GPRD practice during the
hospital admission for myocardial infarction, or with less than
one year of follow-up before their myocardial infarction. Patients
were also excluded if there were inconsistencies regarding
patient identifiers between MINAP and GPRD or in timing of
the myocardial infarction in MINAP.
We identified COPD in GPRD by using a list of Read codes
derived from previously published literature (appendix).23 The
COPD code list was applied such that patients were defined as
having COPD if they had a recorded diagnosis of COPD before
or after myocardial infarction. This was done as patients might
not be diagnosed with COPD until they have symptoms, at
which point they usually have GOLD stage III or IV disease.
As such they will have had COPD for some time before their
diagnosis. In a sensitivity analysis, however, we redefined
individuals’ COPD status based only on the presence or absence
of a COPD diagnosis before their myocardial infarction. We
developed and used a code list for exacerbations of COPD
(appendix) within the patients with COPD to identify
exacerbations.We classified patients as having an exacerbation
if the patient had an exacerbation code and was prescribed a
predefined antibiotic or oral prednisolone, or both. We chose
this method to maximise the likelihood of an exacerbation truly
being an exacerbation, but this could have led to an
underestimation of the true number of exacerbations
experienced. As treatment was included in the definition of
exacerbation, the presence of two or more exacerbations a year
was defined as frequent exacerbations.24
Information on COPD (including disease severity by GOLD
staging and MRC score), demographic factors (age in
approximate quarters, sex, ethnicity), previous cardiovascular
disease (angina, heart failure), cardiovascular risk factors
(hypertension, diabetes, dyslipidaemia, family history, smoking
history (current, former, or never), peripheral arterial disease,
cerebrovascular disease), and drug prescriptions (aspirin, statins,
angiotensin converting enzyme inhibitors, β blockers, and drugs
for COPD) were obtained from GPRD. In addition, MINAP
data provided information on results of electrocardiography at
the time of presentation, type of myocardial infarction, markers
of severity of infarct (peak troponin concentrations), smoking
status at admission, drugs given on admission, and drugs on
discharge, including prescription of β blockers. Cut points for
hypertension reflected National Institute for Health and Clinical
Excellence (NICE) guidelines.22
The use of β blockers during the hospital admission for
myocardial infarction was obtained from MINAP only. The β
blocker variable in MINAP used to identify whether or not
patients were prescribed a β blocker during the hospital
admission for myocardial infarction was coded as “yes” if a β
blocker was continued from before admission or newly started
during the hospital admission for myocardial infarction and
continued at the time of discharge from hospital. Patients not
prescribed a β blocker at myocardial infarction were coded as
“no.” Other coding options included in this variable were β
blocker contraindicated, not applicable, not indicated, or
missing. These individuals were never included in the dataset
so that we did not introduce misclassification (fig 1⇓).
TheMINAP variable used to ascertain β blocker use was coded
such that the β blocker could have been started at any point
from the day of admission for the myocardial infarction and
was then continued on discharge. We assumed that β blockers
would be started as soon as possible after admission for
myocardial infarction and therefore took the day of myocardial
infarction as the start date of β blocker use. No information
from after discharge fed into the classification of patients into
the three β blocker groups. We used information from GPRD
to ascertain β blocker use before the myocardial infarction and
long term use afterwards. The date of the last prescription in
GPRD was used to determine length of treatment. Median
duration of use was calculated based on prescription length.
Patients were not required to have two prescriptions to be
included in the β blocker exposed group as this would have
introduced an immortal time bias. Immortal time bias can occur
when determination of treatment status for an individual involves
a delay in which follow-up time is still accrued. No patient had
only one prescription on the day of myocardial infarction.
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Primary outcome
The primary outcome was all cause mortality after a first ST
elevation (STEMI) or non-ST elevation myocardial infarction
(NSTEMI) in patients with COPD prescribed and not prescribed
a β blocker during the hospital admission for myocardial
infarction. Information on death was based on data from Office
for National Statistics death certificates. Cause specific
mortality, broken down into cardiac and non-cardiac causes
based on ICD-10 (international classification of diseases, 10th
revision) codes from death certificate data, was investigated in
a secondary analysis. We also investigated short term (one year)
all cause mortality in a sensitivity analysis.
Analyses
We used χ2 tests to compare demographic factors, the prevalence
of risk factors before myocardial infarction, and drugs and
management at the time of and after myocardial infarction in
patients with COPD prescribed or not prescribed β blockers
during the hospital admission for myocardial infarction. Crude
mortality rates were calculated. We analysed time from
myocardial infarction (that is, the date of the myocardial
infarction) to death using Cox proportional hazards models to
produce adjusted hazard ratios to determine whether mortality
differed between those prescribed and not prescribed a β blocker
during the hospital admission for myocardial infarction. To
investigate the effect of timing of prescription of β blockers,
we divided people into those with no evidence of β blocker
prescription over the study period, those who had been
prescribed β blockers before their myocardial infarction, and
those prescribed β blockers for the first time in the immediate
aftermath of their myocardial infarction (during their hospital
admission). Smoking status, age, and sex were included in all
models as they were deemed a priori to be probable confounders.
We then added all measured confounders cumulatively to the
model in a model building table. These included age, sex,
smoking, the presence of family history of cardiovascular
disease, angina, hypertension, dyslipidaemia, peripheral arterial
disease, cerebrovascular disease, heart failure and diabetes
before myocardial infarction, frequency of exacerbations of
COPD, type of myocardial infarction, and drug use at the time
of or before myocardial infarction (diuretics, anti-arrhythmia
drugs, antiplatelet agents, angiotensin converting enzyme
inhibitor, statins, nitrates, and calcium channel blockers). Data
were managed and the analysed with STATA 11.
To investigate the duration of β blocker use from the time of
myocardial infarction, we analysed these data using time to
event Kaplan Meier methods for time to stopping. We defined
stopping as the date of the last prescription plus the median
length of time between prescriptions.
Sensitivity analyses and propensity scores
Sensitivity analyses were performed to explore possible effects
of misclassification with respect to the timing of the diagnosis
of COPD by repeating the analysis including only those with a
diagnosis made before their myocardial infarction.25 Propensity
scores (the propensity for being prescribed a β blocker during
the hospital admission for myocardial infarction) were used as
an alternative way of adjusting for differences in groups of
patients with COPD prescribed and not prescribed a β blocker.
We included in the propensity score all covariates included in
the model building table and obtained a final hazard ratio
adjusted for propensity score. This allowed us to determine
whether patients prescribed and not prescribed a β blocker were
truly comparable. The covariates that contributed to the final
propensity score hazard ratio included age; sex; smoking; a
family history of cardiovascular disease, angina, hypertension,
dyslipidaemia, peripheral arterial disease, cerebrovascular
disease, heart failure, and diabetes before myocardial infarction;
frequency of exacerbations; type of myocardial infarction; and
drug use at the time of or before myocardial infarction, including
diuretics, anti-arrhythmia drugs, antiplatelet agents, angiotensin
converting enzyme inhibitor, statins, nitrates, and calcium
channel blockers. Propensity scores were calculated with
STATA and adjusted for as a categorical variable in the analysis
(using logistic regression with death as the outcome) to give a
final ratio. In a sensitivity analysis we also included GOLD
staging and infarct severity (peak troponin concentrations) in
the model. We did not include GOLD staging or infarct severity
in the main analysis as data were not available in all patients.
We also undertook further sensitivity analyses matching on
propensity scores (1:1 matching, each exposed patient was
matched to an unexposed patient whose propensity score was
within +/−0.01). We re-ran the analysis using the date of
admission plus one day and date of discharge from hospital as
start time for follow-up (that is, excluding some/all individuals
who died in hospital) as we did not know the exact timing of
starting the β blocker in hospital but had assumed it to be the
same date as the myocardial infarction for the main analysis.
Results
Of the 2209 patients with COPD identified in MINAP with a
first myocardial infarction with the inclusion and exclusion
criteria applied, 1146 (51.8%) were excluded as β blockers were
not coded yes/no. In 679 (59.2%) β blockers were coded as
being contraindicated, but we do not have details on why. We
included 1063 patients in the analysis (fig 1⇓). Patients with
COPD prescribed a β blocker during the hospital admission for
myocardial infarction were younger and less likely to have a
history of hypertension, cerebrovascular disease, peripheral
arterial disease, heart failure, dyslipidaemia, or angina before
their myocardial infarction. They were also more likely to have
infrequent exacerbations and less likely to have been prescribed
diuretics before the myocardial infarction (table 1⇓).
Data on FEV1 and height were available in 600 patients (56%),
allowing us to calculate FEV1% predicted and GOLD staging
in this group. GOLD staging was similar in those prescribed
and not prescribed a β blocker. Table 2 provides information
on COPD drugs and cardiac drugs prescribed before the
myocardial infarction⇓. Table 3 shows other cardiac drugs
prescribed during the hospital admission for myocardial
infarction.⇓
The β blockers prescribed during the hospital admission for
myocardial infarction were predominantly cardioselective, and
data were available on 193 (82.8%) of patients. Bisolprolol was
most commonly prescribed (111, 57.5%), followed by atenolol
(48, 24.9%), metoprolol (22, 11.4%), carvedilol (7, 3.6%),
nebivolol (2, 1.0%), propranolol (2, 1%), and sotalol (1, 0.5%).
Survival analysis
The median length of follow-up after myocardial infarction was
2.9 years (range 0.09-7.2 years). After adjustment for history
of smoking and sex and stratification by age, patients with
COPD prescribed a β blocker during the hospital admission for
myocardial infarction and those prescribed a β blocker before
the myocardial infarction had better survival than those never
prescribed a β blocker: hazard 0.45 (95% confidence interval
0.34 to 0.60, P<0.001) and 0.72 (0.57 to 0.90, P=0.004),
respectively (fig 2⇓).
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With respect to prescription of a β blocker during the hospital
admission for myocardial infarction, the addition of covariates
to the model did not significantly alter the hazard ratio (table
4⇓; fully adjusted hazard ratio 0.50, 95% confidence interval
0.36 to 0.69; P<0.001). With adjustment for all covariates there
was also a survival benefit in patients prescribed a β blocker
before myocardial infarction compared with those never
prescribed a β blocker (0.59, 0.44 to 0.79; P<0.001).
With adjustment for all covariates and one year survival as the
outcome, there was a short term survival benefit in patients
prescribed a β blocker during the hospital admission for
myocardial infarction compared with those never prescribed a
β blocker (fully adjusted hazard ratio 0.48, 95% confidence
interval 0.30 to 0.76; P=0.002). There was also a short term
survival benefit in patients already taking a β blocker before
myocardial infarction compared with those never prescribed a
β blocker (0.68, 0.46 to 1.0; P=0.05).
Causes of death
Cardiac and non-cardiac deaths were similar in patients with
COPD prescribed and not prescribed a β blocker during the
hospital admission for myocardial infarction (49% and 51%,
respectively; table 5⇓). After adjustment for age, sex, history
of smoking, and frequency of exacerbations, survival analysis
with cardiac and non-cardiac death as the outcome showed an
improved survival in those prescribed a β blocker compared
with those not prescribed a β blocker during the hospital
admission for myocardial infarction (hazard ratio for cardiac
deaths 0.57 (95% confidence interval 0.38 to 0.86; P=0.03) and
non-cardiac deaths 0.49 (0.32 to 0.75; P=0.01), respectively.
Sensitivity analyses and propensity scores
We undertook several sensitivity analyses (table 6⇓), including
matching on propensity score and using propensity score as a
variable in the Cox proportional hazards model, using all
covariates included in the previous model (see table 4). When
we repeated the analysis splitting patients into only two
group—those taking β blockers or not at discharge from hospital
for myocardial infarction irrespective of previous use— the
results were not significantly different. Adjustment for possible
variation in start date of β blockers during the hospital admission
for myocardial infarction did not significantly alter the outcome.
When we started follow-up from day of admission plus one day
or from date of discharge from hospital, the effect size was
slightly attenuated, but we observed a similar protective effect
of β blockers initiated during hospital admission for myocardial
infarction.
Prescriptions and tolerability of β blockers
after myocardial infarction
Of patients with COPD who died in hospital, 15.2% (10/66)
were prescribed a β blocker compared with 22.4% (223/997)
of those who survived their hospital admission. Of those
prescribed a β blocker during the hospital admission for
myocardial infarction, 203 (87.1%) were still taking a β blocker
at six months, 185 (79.4%) were still receiving prescriptions
for a β blocker at one year, and 142 (60.9%) at two years. The
median time to stopping β blockers was 3.5 years. All patients
prescribed a β blocker during the hospital admission for
myocardial infarction had subsequent prescriptions from their
general practitioner. Of the 244 patients taking a β blocker
before the myocardial infarction, 87 (35.7%) had the β blocker
stopped on admission. A total of 38.6% of the study population
started taking a β blocker at myocardial infarction or continued
taking a β blocker that they were already taking. We do not
have any data to suggest that β blockers were used in preference
to calcium channel blockers.
Discussion
Principal findings
In this large population based study we showed that among
people with COPD, use of a β blocker after a first myocardial
infarction was associated with lower subsequent mortality. Only
38.6% of people with COPD, however, received a β blocker
during the hospital admission for myocardial infarction. This
is the first study to use linked detailed hospital data on
myocardial infarction to the longitudinal clinical records from
primary care to assess mortality after myocardial infarction
among people with COPD. It is also the largest study to date of
the effect of β blockers on survival after myocardial infarction
among patients with COPD.2-6 One of the advantages of this
study is the use of MINAP data, which clearly defines first
myocardial infarction and provides detailed information on
management at the time of the event as well as type and severity
of infarct.
Patients with COPD who were prescribed β blockers were
younger and had less cardiovascular comorbidity and fewer
exacerbations, and, with adjustment for these issues in the
analysis, we found that β blockers still improved survival when
they were prescribed during the hospital admission for
myocardial infarction. Survival after myocardial infarction was
longest in those with COPDwho started taking β blockers during
the hospital admission for myocardial infarction compared with
those already taking them or never prescribed them. Patients
not prescribed β blockers during the hospital admission for
myocardial infarction were more likely to be taking inhalers for
their COPD andmight have been more likely to have symptoms
from their COPD. Patients with COPD prescribed β blockers
during the hospital admission for myocardial infarction are at
a higher risk of death having just had a myocardial infarction
and this might be why they are more effective in this group.
Those prescribed β blockers before myocardial infarction might
have been given β blockers for reasons other than ischaemic
heart disease and thus be a more heterogeneous group.
Comparison with other studies
A 1998 study by Gottlieb and colleagues suggested that the
prescription of β blockers after myocardial infarction in patients
with COPD improved survival.12Even now, however, we found
that β blockers are not prescribed often after myocardial
infarction in such patients, regardless of the type of myocardial
infarction. Tolerability did not seem to be a problem for patients
with COPD, with a median length of prescription 3.5 years after
myocardial infarction. The reluctance to prescribe β blockers
after myocardial infarction in these patients is a worldwide
phenomenon but seems to have diminished as an issue outside
the UK. A recent study based in the US found that discrepancies
in treatment after myocardial infarction between those with and
without COPD has narrowed in recent years, with β blockers
prescribed in over 90% of both groups by 2007.19
We found that the decrease in mortality in those patients with
COPD prescribed a β blocker at myocardial infarction was due
to a reduction in both cardiac and non-cardiac deaths. There
have been suggestions that the benefit of β blockers in these
patients might go beyond cardiac effects, and this could explain
the reduction in non-cardiac deaths.16 17 NICE guidelines on
heart failure now specifically include patients with COPD,18 but
we found that they remain underprescribed in this group. β
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blockers seem to be safe and well tolerated based on these
observational data. Cardioselective β blockers were
predominantly used in this group and are less likely to cause
bronchospasm. There is evidence that β blockers do not
detrimentally affect lung function in patients with COPD16 17
and thus severity of disease or the lack of spirometry at the time
of hospital admission for myocardial infarction should not deter
their prescription. In COPD airways disease is usually poorly
reversible and β blockers should not induce bronchospasm.
Though a randomised controlled trial of β blockers in patients
with COPD could examine some of the perceived safety
concerns that remain around their prescription, there is sufficient
evidence to suggest it would be unethical to withhold β blockers
after myocardial infarction in patients with COPD and perform
a trial of this nature. In addition to increasing evidence of
safety,26 27 there is evidence that they reduce exacerbations and
mortality independent of cardiovascular risk in those with
COPD.28
Patients with frequent exacerbations have more symptoms and
more dyspnoea than those with infrequent exacerbations.29
Physicians might be worried about breathlessness associated
with exacerbations and do not prescribe β blockers in this group.
Those with frequent exacerbations are at risk of cardiovascular
disease and are more likely to have cardiovascular comorbidity
than those with infrequent exacerbations.30 Perhaps we should
be more definite about prescribing β blockers in this group.
Strengths and limitations
Myocardial infarction was defined with rigorous criteria
according to the international definition, and one of the strengths
of this study is the detailed information provided in MINAP
surrounding the diagnosis and management at the time of a
myocardial infarction, including information on the prescription
of β blockers, type of myocardial infarction, and severity of the
infarct (troponin concentrations). We combined information
from GPRD and MINAP and were able to adjust for a wide
range of possible confounders. Another advantage was the
detailed information available on comorbidities and drug
prescriptions both before and after the myocardial infarction.
We used a stringent code list to diagnose COPD and
exacerbations. This approach might have led to an
underestimation of the true number of patients with COPD and
exacerbations in this cohort and therefore an underestimation
of the real survival difference. Prescription records could not
be used to improve the sensitivity of diagnosis of COPD as there
is overlap in the use of drugs for treatment of other respiratory
diseases. Reassuringly, our observed prevalence of COPD was
similar to that from other studies.1 21 23 31 The inclusion of COPD
diagnosis made after the myocardial infarction as well as before
could have reduced misclassification, and sensitivity analyses
confirmed this did not introduce an immortal time bias.32 Most
diagnoses of COPDwere made before or around the time of the
myocardial infarction. The dataset was large, and the overall
percentage of missing data acceptable and small compared with
other methods of data collection.
One of the limitations of this study was the coding of β blocker
use during the hospital admission for myocardial infarction in
MINAP. Patients were more likely to be coded as not being
prescribed a β blocker if they died in hospital. Repeated analysis
with date of discharge from hospital as the start time of
follow-up, however, confirmed that β blockers do have a
protective effect. One of the reasons for the differences in the
effect size comparing start of follow-up from date of myocardial
infarction and start of follow-up at discharge from hospital could
be a potential immortal time bias as patients had to have β
blockers use coded as yes or no to be included in the study, and
to have β blocker use coded, patients were more likely to have
survived the hospital stay. Nonetheless, the overall protective
effect of β blockers was still preserved with change of the start
of follow-up time.
Another limitation of this study is the possible survival bias that
occurs with using MINAP. To be included, patients must have
survived long enough to be admitted to hospital and possibly
even a coronary care unit. Patients with COPD might be less
likely to survive an initial event and might be less likely to be
included in MINAP if their myocardial infarction is slow to be
diagnosed or misclassified as an exacerbation and they are
admitted to a general hospital ward. Though general practices
are self selecting with respect to their contribution to GPRD,
they seem to be representative of the UK population.33 Few
patients within contributing practices refuse to participate at an
individual level, and this is not thought to bias the results. There
were hidden missing variables in GPRD that meant that if data
were missing, they were classified as not present. We were able
to assess the effect of COPD disease severity using only GOLD
staging in a subset of patients. We were also not able to confirm
that the reason for not starting treatment with a β blocker during
the hospital admission for myocardial infarction in the patients
with COPD really was because the patient had COPD. We
cannot be sure that when β blockers were stopped this was
because of poor tolerability. Though efforts weremade to control
for confounding, there might be some residual confounding
(such as unmeasured comorbidities). One of the difficulties with
observational studies is that there could be residual bias and
confounding by contraindication. There is also the risk of healthy
user bias in those patients who take any drug treatment,
including β blockers. While the effect in reality might not be
as large as observed in this study, some protective effect seems
likely, and, in view of these findings, it is difficult to believe
that the effect of β blockers is harmful.
Of patients with COPD excluded from the study, nearly 60%
(679) were not prescribed a β blocker during the hospital
admission for myocardial infarction as the drug was
contraindicated. We do not have any further information on
why the clinician treating the patient thought that β blockers
were contraindicated. While it is possible that some physicians
could have thought that having a diagnosis of COPD was a
contraindication, potentially allowing us to include those
individuals in the analysis, we could not determine this and so
they were excluded. This might have led to a selection bias in
our COPD sample. We did not have information on
comorbidities such as atrial fibrillation, which might also be a
reason for β blockers to be prescribed. We were not able to
assess the effect in patients with severe COPD who were
receiving long term oxygen therapy.
Conclusions and policy implications
The use of β blockers before and at the time of a myocardial
infarction was associated with improved survival in patients
with COPD. Use of β blockers remains limited in patients with
COPD, and this lack of prescribing might be contributing to the
increase inmortality in these patients after myocardial infarction.
Our data suggest that β blockers should be used more widely
in patients with COPD who have had a myocardial infarction.
Safety to date is good in these patients, but further evaluation
of the safety of β blockers in this high risk group might be
required to change current prescribing practice.
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What is already known on this topic
Use of β blockers is associated with reduced mortality after myocardial infarction in the general population
Despite increasing evidence that β blockers are safe and might actually be beneficial in patients with COPD irrespective of myocardial
infarction, they continue to be underprescribed after myocardial infarction in this group
What this study adds
We used detailed data during the hospital admission for myocardial infarction available from MINAP, including type and severity of
myocardial infarction, to investigate β blocker prescription in patients with COPD linked with longitudinal health care records (GRPD)
with adjustment for co-morbidities and other confounders
β blockers are not widely used in patients with COPD who have had a myocardial infarction and could be more widely used
Use of β blockers started either at the time of hospital admission for myocardial infarction or before a myocardial infarction was associated
with improved survival after myocardial infarction in patients with COPD
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Tables
Table 1| Characteristics of 1063 patients with chronic obstructive pulmonary disease (COPD) and timing of β blocker prescription relative
to myocardial infarction. Figures are numbers (percentage) of patients according to use of β blockers
Prescribed β blocker only at
myocardial infarction (n=233,
21.9%)
Took β blocker before myocardial
infarction (n=244, 23.0%)
Never took β blocker (n=586,
(55.1%)TotalCategory
159 (68.2)138 (56.6)354 (60.4)651 (61.2)Men
74 (31.8)106 (43.4)232 (39.6)412 (38.8)Women
Age (years):
43 (18.5)25 (10.3)69 (11.8)137 (12.9)<60
74 (31.8)71 (29.1)160 (27.3)305 (28.7)61-70
72 (30.9)78 (32.0)201 (34.3)351 (33.0)71-80
44 (18.9)70 (28.7)156 (26.2)270 (25.4)>80
57 (24.5)55 (22.5)133 (22.7)245 (23.1)Family history of cardiovascular
disease
Smoking status (n=1060):
10 (4.3)16 (6.6)31 (5.3)57 (5.4)Non-smoker
123 (52.8)142 (58.2)345 (58.9)610 (57.4)Ex-smoker
100 (42.9)86 (35.3)207 (35.3)393 (37.0)Current
46 (19.7)106 (43.4)175 (29.9)327 (30.8)Previous history of angina
97 (41.6)174 (71.3)280 (47.8)551 (51.8)Hypertension
19 (8.2)52 (21.3)95 (16.2)166 (15.6)Dyslipidaemia
22 (9.4)42 (17.2)92 (15.7)156 (14.7)Peripheral arterial disease
17 (7.3)37 (15.2)85 (14.5)139 (13.1)Previous cerebrovascular disease
17 (7.3)43 (17.6)96 (16.4)156 (14.7)Heart failure
12 (5.2)18 (7.4)35 (6.0)65 (6.1)Diabetes
88 (37.8)166 (68.0)362 (61.8)616 (58.0)Diuretics before myocardial
infarction
Frequency of exacerbation:
225 (96.6)226 (92.6)501 (85.5)952 (89.6)Infrequent
8 (3.4)18 (7.4)85 (14.5)111 (10.4)Frequent
MRC breathlessness score (n=429):
20 (17.9)16 (16.8)26 (11.7)62 (14.5)1
41 (36.6)34 (35.8)75 (33.8)150 (35.0)2
33 (29.5)27 (28.4)54 (24.3)114 (26.6)3
17 (15.2)14 (14.7)47 (21.2)78 (18.2)4
1 (0.9)4 (4.2)20 (9.0)25 (5.8)5
Type of myocardial infarction:
90 (38.6)157 (64.3)389 (66.4)636 (59.8)NSTEMI
143 (61.4)87 (35.6)197 (33.6)427 (40.2)STEMI
GOLD staging (n=600):
26 (15.9)12 (31.6)65 (16.3)103 (17.2)1
82 (50.0)16 (42.1)173 (43.5)271 (45.2)2
41 (25.0)6 (15.8)121 (30.4)168 (28.0)3
15 (9.2)4 (10.5)39 (9.8)58 (9.7)4
STEMI=ST elevation MI; NSTEMI=non-ST elevation MI.
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Table 2| Chronic obstructive pulmonary disease (COPD) and cardiac drugs prescribed before myocardial infarction (MI) in 1063 patients
with COPD. Figures are numbers (percentage) of patients according to use of β blockers
Prescribed β blocker only at MI
(n=233, 21.9%)
Took β blocker before MI
(n=244, 23.0%)
Never took β blocker (n=586,
55.1%)Total
21 (9.0)28 (11.5)77 (13.1)126 (11.9)Short acting β agonist or short acting muscarinic
antagonist only
6 (2.6)9 (3.7)25 (4.3)40 (3.8)Long acting β agonist or long acting muscarinic
antagonist only
67 (28.8)78 (32.0)309 (52.7)454 (42.7)Inhaled corticosteroid in combination with above
31 (13.3)63 (25.8)118 (20.1)212 (19.9)Digoxin or amiodarone
70 (30.0)166 (68.0)221 (45.1)457 (47.3)Antiplatelet agents (n=966)
77 (33.1)153 (62.7)188 (38.5)418 (43.3)Angiotensin converting enzyme inhibitor (n=966)
56 (24.0)138 (56.6)161 (32.9)355 (36.8)Statin (n=966)
92 (39.5)190 (77.9)320 (54.6)602 (56.6)Nitrates and calcium channel blockers
88 (37.8)166 (68.0)362 (61.8)616 (58.0)Diuretics
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Table 3| Cardiac drugs prescribed during hospital admission for myocardial infarction (MI) in patients with chronic obstructive pulmonary
disease (COPD) according to use of β blockers
Prescribed β blocker only at MITook β blocker before MINever took β blockerTotal
222 (96.1)176 (81.1)382 (81.5)780 (85.1)Aspirin
198 (87.2)152 (73.1)303 (65.7)653 (72.9)Angiotensin converting enzyme inhibitor
226 (97.8)180 (84.1)359 (77.0)765 (84.0)Statin
109 (82.6)105 (71.9)181 (64.0)395 (70.4)Clopidogrel
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Table 4| Model building table showing hazard ratio for mortality in patients with COPD prescribed β blocker before myocardial infarction
(MI) or during hospital admission for myocardial infarction compared with those never prescribed β blocker, adding explanatory variables
cumulatively to model. In all cases reference category is “never taking a β blocker”
HR (95% CI)
Variable added to model in addition to age, sex, and smoking history β blocker initiated at MIβ blocker before MI
0.45 (0.34 to 0.60)0.72 (0.57 to 0.90)+Family history
0.46 (0.35 to 0.61)0.70 (0.56 to 0.88)+Angina
0.46 (0.35 to 0.61)0.69 (0.55 to 0.87)+Hypertension
0.46 (0.35 to 0.61)0.69 (0.55 to 0.87)+Dyslipidaemia
0.47 (0.35 to 0.62)0.68 (0.54 to 0.85)+Peripheral arterial disease
0.48 (0.36 to 0.63)0.68 (0.54 to 0.86)+Cerebrovascular disease
0.43 (0.32 to 0.59)0.61 (0.47 to 0.81)+Heart failure
0.43 (0.32 to 0.59)0.61 (0.46 to 0.80)+Diabetes
0.46 (0.34 to 0.63)0.62 (0.47 to 0.81)+Type of MI (STEMI compared with NSTEMI)
0.48 (0.35 to 0.66)0.64 (0.48 to 0.84)+Frequent exacerbations
0.52 (0.38 to 0.71)0.64 (0.48 to 0.84)+Diuretics before MI
0.52 (0.38 to 0.72)0.63 (0.48 to 0.83)+Anti-arrhythmia drugs
0.50 (0.36 to 0.69)0.60 (0.45 to 0.80)+Angiotensin converting enzyme inhibitor
0.50 (0.34 to 0.69)0.59 (0.44 to 0.79)+Nitrates and calcium channel blockers
0.50 (0.36 to 0.69)0.59 (0.44 to 0.79)+Anti-platelets
0.50 (0.36 to 0.69)0.59 (0.44 to 0.79)+Statin (fully adjusted model)
STEMI=ST elevation MI; NSTEMI=non-ST elevation MI.
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2013;347:f6650 doi: 10.1136/bmj.f6650 (Published 22 November 2013) Page 11 of 15
RESEARCH
Table 5| Causes of death and timing of prescription for β blocker in patients with chronic obstructive pulmonary disease (COPD) who had
myocardial infarction (MI). Figures are numbers (percentage) of patients according to use of β blockers
Prescribed β blocker only at MI (n=233)Took β blocker before MI (n=244)Never took β blocker (n=586)TotalCause of death
28 (12.7)51 (23.2)141 (64.0)220 (49.0)Cardiac
30 (13.2)44 (19.4)153 (67.4)227 (51.0)Non-cardiac
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Table 6| Sensitivity analyses with different methods for analysis and different start times for follow-up in patients with chronic obstructive
pulmonary disease (COPD) and myocardial infarction (MI). Figures are hazard ratios for β blockers started at admission for MI
P valueHR (95% CI)Sensitivity analysis undertaken
0.030.56 (0.34 to 0.93)Using only diagnoses of COPD before MI instead of before and after
<0.0010.57 (0.43 to 0.77)Adjusted for propensity score as categorical variable in analysis
<0.0010.42 (0.28 to 0.63)Matching on propensity score
0.020.41 (0.26 to 0.66)Adding GOLD stage to model
<0.0010.53 (0.37 to 0.74)Adding infarct severity to model (troponin)
0.030.59 (0.37 to 0.94)Repeated analysis splitting patients into only two groups: those taking β blockers or not at discharge from hospital admission for MI
irrespective of use before MI
<0.0010.54 (0.39 to 0.75)Using day of admission +1 as start time of follow-up
0.020.64 (0.44 to 0.94)Follow-up started from date of discharge
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Figures
Fig 1 Flow chart showing patients included and excluded from analysis identified from MINAP (Myocardial Ischaemia
National Audit Project)
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Fig 2 Kaplan-Meier curve showing estimated survival (and 95% confidence intervals) after myocardial infarction in patients
with COPD prescribed β blocker before myocardial infarction, during hospital admission for myocardial infarction, or never,
excluding deaths on day of diagnosis
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